List of Excipients in Branded Drug COLYTE

COLYTE Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 30, 2026

COLYTE is a polyethylene glycol 3350-electrolyte bowel-preparation product. Its commercial value is driven less by composition-of-matter exclusivity than by tolerability, flavor acceptance, packaging, distribution, and manufacturing economics. The core formulation is mature and readily replicable, while differentiated excipient systems can support line extensions, private-label products, pediatric presentations, and lower-volume regimens.

What is the COLYTE formulation?

COLYTE is supplied as a powder for reconstitution into an electrolyte-balanced oral lavage solution. The formulation uses polyethylene glycol 3350 to retain water in the gastrointestinal tract while sodium and potassium salts reduce net electrolyte movement.

Component	Function	Approximate amount per 1-gallon reconstituted solution
Polyethylene glycol 3350	Osmotic lavage agent	227.1 g
Sodium sulfate	Electrolyte and osmotic component	21.5 g
Sodium chloride	Sodium and chloride replacement	5.53 g
Potassium chloride	Potassium replacement	2.86 g
Sodium bicarbonate	Buffer and electrolyte	6.36 g
Flavor system	Taste masking and patient acceptability	Product-specific
Water	Vehicle after reconstitution	Quantity sufficient

The precise commercial presentation, flavor packet composition, labeling language, and excipient inventory must be taken from the current FDA-approved package insert and product labeling. The core active formulation is described in FDA labeling and DailyMed records for COLYTE with flavor packs.[1,2]

Which ingredients are active and which are excipients?

For COLYTE, the formulation should not be analyzed using a simple conventional distinction between “drug substance” and “inactive ingredient.”

Polyethylene glycol 3350 and the electrolyte salts are the pharmacologically relevant formulation components. The flavor system, sweeteners, colorants, processing aids, and packaging materials are the principal excipient and product-design variables.

This classification matters commercially. A competitor generally cannot remove or materially alter the electrolyte system without affecting the product’s clinical and regulatory profile. Flavor, sweetness, powder flow, reconstitution, packaging, and patient instructions provide more practical room for differentiation.

What excipients are protected by COLYTE patents?

COLYTE’s core formulation is an old, genericized polyethylene glycol-electrolyte lavage concept. The principal commercial barriers are unlikely to be current composition-of-matter patents covering polyethylene glycol 3350 or the basic electrolyte combination.

The most relevant potential protection categories are:

1. Flavor and sweetener combinations.
2. Powder manufacturing and blending processes.
3. Sachet or container configurations.
4. Low-volume dosing regimens.
5. Stability improvements.
6. Ready-to-drink or concentrated presentations.
7. Specific methods of bowel cleansing before procedures.
8. Pediatric or patient-specific administration protocols.

The commercial importance of these categories depends on whether a patent is listed in the FDA Orange Book, remains enforceable, covers the marketed product, and can withstand validity and infringement challenges.

What is the Orange Book status of COLYTE?

COLYTE is an established prescription bowel-preparation product with generic competition. The FDA Orange Book should be reviewed for the current NDA, listed patents, and exclusivity entries before making a launch or litigation decision.[3]

For a mature PEG-electrolyte lavage product, the likely strategic conclusion is:

• No meaningful remaining new-drug exclusivity for the original product.
• Limited or no dependence on a current composition patent.
• Greater relevance of formulation, packaging, method-of-use, or process patents.
• High probability that generic competition can proceed through the ANDA pathway if the proposed product meets applicable sameness and bioequivalence requirements.

A live patent number, expiration date, or Paragraph IV assessment should not be inferred from the brand’s historical approval. Patent coverage must be tied to the current NDA and Orange Book listing.

When does COLYTE lose exclusivity?

COLYTE’s original regulatory exclusivity has expired. The product is in the genericized phase of its lifecycle.

Exclusivity category	COLYTE commercial position
New chemical entity exclusivity	Expired
Five-year NCE exclusivity	Not relevant to this mature product
Three-year new clinical investigation exclusivity	No apparent current relevance
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No apparent current commercial effect
Composition-of-matter patent	Unlikely to provide meaningful current protection
Formulation or method patents	Must be verified against current Orange Book and patent records

The main timing issue is therefore not the original COLYTE exclusivity date. It is whether a new product modification can obtain separate protection or regulatory exclusivity.

What Paragraph IV challenges affect COLYTE?

Paragraph IV litigation is generally relevant when an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed.

For a mature electrolyte lavage product, Paragraph IV exposure is likely to be limited unless the reference product has listed patents covering a specific formulation, delivery format, or use. The absence of a composition patent reduces the opportunity for a brand company to delay generic entry through a conventional patent strategy.

A potential entrant should examine:

• Current Orange Book patent listings for the COLYTE reference product.
• Any 30-month litigation stays.
• FDA tentative approvals associated with Paragraph IV certifications.
• Patent settlements involving polyethylene glycol-electrolyte bowel preparations.
• Whether the proposed product uses the same flavor system, dosage instructions, and container configuration.
• Whether the proposed labeling creates a method-of-use issue.

The economics generally favor design-around strategies over litigation where the alleged patent concerns flavor, packaging, or a nonessential process.

What formulation patents could create commercial value?

The strongest patent opportunities are likely to involve measurable technical improvements rather than the basic COLYTE composition.

Taste-masking systems

Taste is a major adherence variable for bowel preparations. Suitable patent subjects could include:

• Specific combinations of acids, sweeteners, and flavors.
• Reduced aftertaste formulations.
• Flavor systems that remain stable during storage.
• Flavor packets added immediately before use.
• Natural flavor systems with reduced regulatory and supply-chain risk.
• Formulations that mask sulfate bitterness without increasing sodium or potassium load.

A taste patent is more defensible when it identifies a narrow composition with demonstrated sensory or compliance benefits.

Lower-volume formulations

Patients frequently prefer lower-volume bowel preparations. A lower-volume COLYTE-style product could use:

• More concentrated PEG-electrolyte powder.
• Split-dose administration.
• An adjunct clear-liquid protocol.
• A separate flavor or electrolyte packet.
• A ready-to-drink product with improved palatability.

The regulatory burden rises if the lower-volume regimen changes cleansing efficacy, hydration, renal-risk management, or administration instructions.

Stability and reconstitution

Useful technical targets include:

• Longer post-reconstitution stability.
• Improved powder flow and reduced segregation.
• Faster dissolution.
• Reduced foaming.
• Improved resistance to humidity during storage.
• Single-use sachets with lower moisture transmission.
• Packaging that reduces dosing errors.

These improvements can support both process patents and product differentiation, although a competitor may design around a narrow manufacturing claim.

Pediatric and special-population products

Pediatric bowel preparation is a potential niche for:

• Lower osmotic burden.
• Age-specific flavor systems.
• Smaller sachets.
• Dosing by weight or age.
• Reduced sodium or potassium exposure where clinically appropriate.
• Clear administration instructions for caregivers.

Any pediatric positioning requires clinical and regulatory support. A flavor change alone is unlikely to justify a new prescription product unless it produces a meaningful adherence or safety benefit.

How does COLYTE compare with competing bowel preparations?

Product category	Main formulation strategy	Commercial advantage	Main weakness
COLYTE-type PEG-electrolyte lavage	High-volume PEG plus balanced electrolytes	Established safety and efficacy profile	Large volume and poor palatability
Lower-volume PEG-electrolyte products	Reduced lavage volume with adjunct fluid	Better patient convenience	Higher dependence on instructions and hydration
Sulfate-based preparations	Sodium sulfate and related salts	Lower administered volume in some regimens	Electrolyte and renal-risk considerations
Sodium phosphate products	Phosphate osmotic load	Effective at low volume	Greater renal and electrolyte concerns
Magnesium-based products	Magnesium salts with other osmotic agents	Low-volume options	Renal and electrolyte limitations
Ready-to-drink solutions	No patient reconstitution step	Convenience and dosing consistency	Higher shipping, packaging, and stability costs

COLYTE competes primarily on clinical familiarity and balanced electrolyte design. It is vulnerable on volume, taste, and preparation burden.

What commercial opportunities exist for COLYTE excipients?

1. Premium flavor and adherence platform

A supplier could develop a proprietary flavor-and-sweetener system for PEG-electrolyte solutions. The value proposition would be reduced bitterness, lower nausea, and improved completion rates.

Commercial models include:

• Licensing the flavor system to generic manufacturers.
• Supplying a proprietary flavor packet.
• Developing a co-branded bowel-preparation product.
• Providing a formulation package for a 505(b)(2) or ANDA applicant.

The strongest opportunity is a flavor system that works across several PEG-electrolyte products rather than one COLYTE-specific formulation.

2. Private-label generic platform

A contract manufacturer could offer a complete platform comprising:

• PEG-electrolyte powder.
• Flavor packets.
• Sachet packaging.
• Reconstitution instructions.
• Stability data.
• Analytical methods.
• Regulatory documentation.

This model can reduce development time for regional pharmaceutical companies and pharmacy chains.

3. Improved powder and packaging system

A moisture-resistant single-dose sachet can improve shelf life, shipping stability, and reconstitution. The opportunity is particularly relevant because electrolyte powders can segregate, cake, or dissolve unevenly when exposed to humidity.

Potential revenue sources include:

• Packaging technology licensing.
• Contract filling.
• Proprietary laminate materials.
• Multi-sachet kits.
• Automated dispensing formats.

4. Patient-centric formulation

A product that allows patients to customize flavor without changing the electrolyte dose may have commercial value. Examples include separate citrus, berry, or unflavored packets, provided the added components remain compatible with the label and do not introduce dosing or safety problems.

5. Global-market adaptation

The core formulation can be adapted for markets with different requirements for:

• Sodium content.
• Sweeteners.
• Colorants.
• Preservatives.
• Flavor ingredients.
• Sachet sizes.
• Prescription versus over-the-counter status.
• Local language and dosing instructions.

Geographic expansion is more likely to depend on local registration, manufacturing, and distribution than on U.S. patent protection.

What regulatory pathway applies to a COLYTE follow-on?

A conventional same-formulation generic would generally be evaluated through the ANDA pathway if it can demonstrate pharmaceutical equivalence, bioequivalence where required, and conformity with the reference product’s quality attributes.

A materially modified product may require a 505(b)(2) application. This is more likely where the sponsor changes:

• Concentration.
• Administration volume.
• Flavor or sweetener system with a clinically relevant effect.
• Dosage regimen.
• Dosage form.
• Packaging that changes administration.
• Pediatric use.
• Ready-to-drink presentation.

The sponsor must determine whether a proposed excipient change is pharmaceutical, clinical, or labeling-relevant. A flavor change may be commercially significant but still require limited regulatory support compared with a change in osmotic load or electrolyte composition.

What manufacturing and intellectual-property barriers exist?

The manufacturing barrier is moderate rather than high. The formulation uses widely available raw materials, but commercial-scale production requires control of:

• PEG particle size.
• Salt uniformity.
• Powder segregation.
• Moisture uptake.
• Sachet fill weight.
• Dissolution time.
• Microbiological quality after reconstitution.
• Flavor stability.
• Container-closure integrity.

The intellectual-property barrier is lower for the base composition and higher for differentiated products. A credible patent position would require claims directed to a defined excipient combination, a reproducible manufacturing parameter, a specific package, or a clinically supported administration method.

Trade secrets may be more valuable than patents for:

• Flavor ratios.
• Powder blending sequence.
• Humidity controls.
• Packaging specifications.
• Supplier qualification.
• Sensory testing protocols.

Which companies are challenging or competing with COLYTE?

Competition comes from generic PEG-electrolyte manufacturers, branded lower-volume bowel-preparation companies, and suppliers of alternative osmotic regimens. The competitive landscape includes:

• Generic versions of PEG-electrolyte lavage solutions.
• Lower-volume PEG products.
• Sulfate-based products.
• Magnesium-based products.
• Sodium picosulfate and magnesium oxide combinations.
• Hospital and pharmacy private-label products.

The relevant competitive metric is not only prescription volume. A sponsor should track:

• Completed bowel preparations.
• Procedure cancellation rates.
• Patient adherence.
• Payer formulary placement.
• Average selling price.
• Pharmacy substitution.
• Hospital purchasing contracts.
• Gastroenterology practice preferences.
• Net revenue after rebates.

What generic launch risks exist?

A COLYTE follow-on faces four principal risks:

1. Clinical differentiation risk. A lower-volume or sweeter product may not deliver sufficient cleansing or tolerability improvement.
2. Regulatory risk. Changes to electrolyte concentration or dosing instructions can move the product beyond a routine generic pathway.
3. Pricing risk. A basic generic product may face rapid price erosion.
4. Supply-chain risk. Salts, PEG, flavor ingredients, and moisture-resistant packaging must remain consistently available.

A differentiated excipient strategy can reduce pricing pressure, but the improvement must be visible to prescribers, payers, patients, or pharmacies.

How strong is the COLYTE patent estate?

The base COLYTE patent estate is likely weak as a barrier to generic entry because the product is mature and its principal formulation concept is established. The stronger protection opportunities are incremental:

IP category	Expected strategic strength
PEG 3350 composition	Low
Basic PEG-electrolyte combination	Low
Flavor system	Moderate if narrowly claimed and technically supported
Low-volume regimen	Moderate to high if clinically differentiated
Packaging	Moderate
Manufacturing process	Moderate
Method of bowel cleansing	Variable
Trade secrets	Moderate for formulation and process know-how

Patent strength should be evaluated claim by claim. A patent that covers only a replaceable flavor or packaging feature may have limited ability to prevent a generic launch.

Key Takeaways

• COLYTE is a mature PEG 3350-electrolyte lavage product with limited apparent value from basic composition exclusivity.
• The principal excipient opportunities are taste masking, sweetness, stability, powder handling, and packaging.
• Lower-volume and ready-to-drink presentations offer greater commercial differentiation than a conventional high-volume generic.
• A same-formulation product is more likely to fit the ANDA pathway; material regimen or formulation changes may require a 505(b)(2) application.
• There is no biosimilar issue because COLYTE is a small-molecule oral solution, not a biologic.
• Current Orange Book listings, FDA approval records, and litigation databases should control any patent-expiration or Paragraph IV conclusion.
• Manufacturing know-how and supply-chain execution may provide more practical protection than broad patent claims.
• The most attractive business model is a platform combining improved flavor, moisture-resistant packaging, regulatory support, and private-label manufacturing.

FAQs

Can a new flavor of COLYTE support a separate pharmaceutical product?

Yes, but a flavor-only change usually has limited exclusivity value. Commercial differentiation is stronger when the flavor system improves completion, nausea, dissolution, or storage stability and is supported by defensible formulation data.

Is polyethylene glycol 3350 an excipient in COLYTE?

Polyethylene glycol 3350 is the principal osmotic lavage component and should be treated as an active formulation ingredient for regulatory and technical analysis. It is not equivalent to a conventional inactive excipient such as a flavor or colorant.

Does COLYTE have biosimilar competition?

No. COLYTE is an oral small-molecule electrolyte lavage solution. Competition occurs through generic and alternative bowel-preparation products, not biosimilar pathways.

Can a manufacturer sell a COLYTE-style product without the COLYTE brand?

Yes, subject to FDA approval, applicable ANDA requirements, trademark restrictions, labeling rules, manufacturing controls, and any enforceable patent or regulatory exclusivity rights associated with the reference product.

What is the highest-value excipient opportunity for a COLYTE competitor?

A validated taste-masking and adherence platform combined with moisture-resistant unit-dose packaging is likely to offer the best balance of technical differentiation, regulatory practicality, and commercial value.

References

1. U.S. Food and Drug Administration. (n.d.). COLYTE with flavor packs: Prescribing information. FDA Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

2. National Library of Medicine. (n.d.). COLYTE with flavor packs: Drug label. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-approvals

5. United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary. USP. https://www.usp.org/usp-nf